Magurol (doxazosin) tablets 4 mg. №20

Description

Magurol composition
active substance: doxazosin;
1 tablet contains doxazosin mesylate 4.86 mg equivalent to doxazosin 4 mg;
excipients: lactose monohydrate; microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate, sodium lauryl sulfate.

Dosage form
Tablets.

Pharmacological properties
This drug Magurol belongs to the group of antihypertensive drugs, alpha-adrenergic receptor antagonists.
The main active ingredient, doxazosin, is a selective blocker of alpha-1, a subtype of postsynaptic adrenergic receptors. As a result, it has a vasodilating (vasodilating) effect.
It is distinguished from non-selective alpha-blockers by the lack of addiction to this drug with prolonged use.
It is usually used in the treatment of arterial hypertension. Doxazosin is able to reduce systemic vascular resistance. The maximum decrease in pressure is observed 2-6 hours after the use of the drug and is associated with a slight increase in heart rate.
Magurol is effective in lowering systolic and diastolic blood pressure in both standing and supine positions. At the same time, the effect is more pronounced when standing.
Able to reduce cholesterol and low density lipoprotein cholesterol.

Indications
This drug Magurol is most often used to treat hypertension. In particular, for the treatment of mild to moderate essential hypertension (in combination with thiazide diuretics and / or other antihypertensive drugs).
It is permissible to use it as a monopreparation, if necessary.
It is also used in complex therapy in the treatment of benign prostatic hyperplasia, since the drug helps to increase the urine flow rate and improve the corresponding symptoms. In this case, it is permissible to use this medicine even if the patient has normal blood pressure, since doxazosin does not cause a clinically significant decrease in blood pressure in this case.
With high blood pressure, the drug will have a positive effect on the treatment of both diseases.

Contraindications
Not applicable if the patient has hypersensitivity (allergy) to one of the components that make up the drug.
Use is contraindicated in:

• chronic urinary retention;
• large residual amount of urine (more than 200 ml);
• chronic fibrous or granulomatous prostatitis;
• stricture of the urethra;
• past pelvic radiation therapy;
• stones in the prostate or bladder;
• an increase in the average lobe of the prostate;
• macrohematuria, epididymitis;
• diabetes mellitus, parkinsonism;
• hydronephrosis;
• prostate cancer;
• myocardial infarction;
• transient ischemic attacks;
• cerebrovascular episodes in the previous 6 months.

It is also contraindicated to use if the patient has ever undergone surgery on the prostate gland in the past.

Children
Not recommended for use in pediatrics.

Application during pregnancy and lactation
The use of this drug in pregnant women or in women during the period when breastfeeding is carried out is performed as directed by a doctor and with great care. In general, this drug is not recommended for use in pregnant women.
It is advisable to suspend lactation during treatment.

Method of administration and dosage
Adults use Magurol as directed by a doctor, who selects the dosage on an individual basis.
It is taken once a day, in the morning or in the evening, with water, regardless of the meal.
In the course of therapy, constant and careful monitoring of the level of blood pressure is necessary, especially if combination therapy is used in conjunction with other antihypertensive drugs, diuretics.
The dose of the drug can vary from 1 to 16 mg per day. The initial dosage is 1 mg. Exceeding the initial dosage is not allowed to avoid negative side effects.
In the future, it is possible to increase the dosage, if necessary, to that at which the necessary hypertensive effect is achieved. The average dosage is 1-8 mg per day. The maximum decrease in pressure is observed after 2-6 hours.
If the dosage is increased above 4 mg per day, the likelihood of postural effects increases, in particular, syncope, postural hypotension.
In benign hyperplasia, the drug is taken in an initial dosage of 1 mg of doxazosin per day. The dose may be increased depending on the characteristics of the patient’s urodynamics. If necessary, the dose can be increased to 2, then to 4 or 8 mg per day, which is the maximum allowable dosage for this disease.
The dose may be increased at a frequency of once every 1-2 weeks. Regular monitoring of blood pressure levels is required.
If the drug gave significant side effects or did not show sufficient efficacy when the maximum dosage was reached, the drug should be discontinued.
The duration of the course of treatment is determined by the attending physician, depending on the severity of the course of the disease and the individual reaction of the body to the drug.

Overdose
Overdose can cause severe hypotension or syncope.
In this case, it is necessary to monitor the functioning of the kidneys, the level of blood pressure, actions to normalize the pressure – increase the volume of the circulating blood volume, and take vasopressor drugs.
Dialysis is ineffective.

Side effects
Usually, patients tolerate the use of the drug well.
In some cases, side effects occur in the form of:

• dizziness, increased heartbeat, vertigo, tachycardia, postural hypotension, arrhythmia;
• itching, skin rashes;
• myalgia, arthralgia;
• headache, drowsiness, sexual dysfunctions, paresthesia, insomnia, anxiety, nervousness, hypoesthesia, sweating, hot flashes, tremors;
• visual impairment, visual accommodation, conjunctivitis, tinnitus;
• nausea, vomiting, diarrhea, flatulence;
• shortness of breath, rhinitis, nosebleeds, sinusitis, bronchospasm, bronchitis;
• frequent urination, polyuria, urinary incontinence, urinary disorders;
• fatigue, chest pain, asthenia, muscle spasms, pain, facial edema, weight gain, generalized edema;
• decrease in the number of platelets, decrease in the number of leukocytes, decrease in hematocrit, hemoglobin, neurophils.

If you have any unusual side effects as a result of taking this drug, you should consult your doctor about possible changes in the treatment regimen.

Storage conditions and periods
The shelf life of the drug Magurol is no more than 5 years from the production date indicated on the package.
Store in a dry place, protected from direct exposure to sunlight, out of the reach of children, at a temperature not exceeding 25 ° C.